Coherus BioSciences has struck a deal to acquire exclusive rights from Bioeq to commercialize the firm’s proposed biosimilar to Lucentis (ranibizumab) in the US. Swiss biopharmaceutical joint venture Bioeq plans to file a Biologics License Application with the US Food and Drug Administration in the fourth quarter of 2019, with Coherus planning to launch the product in 2021.
Coherus said it would “apply its proficiencies and infrastructure developed for the oncology therapeutic commercial environment to the ophthalmology therapeutic...





